FARALLON CAPITAL MANAGEMENT LLC
Q4 2022 13F-HR Holdings
Net value change ($000)
-1,566,100
(-9.3%)
New positions
11
Sold out positions
48
Turnover %
22.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| INTU | 351,115 | NEW |
| CRM | 204,856 | 69.1% |
| BABA | 197,292 | 531.6% |
| SPGI | 141,675 | 64.7% |
| AZN | 92,145 | 30.1% |
| IQV | 86,534 | 14.9% |
| BIIB | 82,562 | 101.2% |
| NOW | 73,248 | 39.3% |
| TMO | 70,782 | 12.4% |
| MSFT | 69,746 | 20.8% |
Top Reduces (Value $000, Stocks/ETFs)
| Change Healthcare Inc. | -496,917 | -100.0% |
| TWTR | -339,979 | -100.0% |
| Biohaven Pharmaceutical Holding Co Ltd. | -294,452 | -100.0% |
| CLVT | -254,150 | -66.8% |
| META | -245,179 | -100.0% |
| ADBE | -191,201 | -100.0% |
| Horizon Therapeutics Public Ltd Co | -110,178 | -100.0% |
| BEKE | -94,084 | -53.9% |
| NIELSEN HLDGS PLC | -68,495 | -100.0% |
| AVTR | -60,972 | -84.5% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
1,453,234
(9.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|